Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(50.0%)
N/A
1(50.0%)
2Total
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04876534Phase 2Unknown

Tocilizumab in Active Moderate-severe Graves' Orbitopathy

Role: collaborator

NCT05138094Not ApplicableUnknown

LIVACOR Trial: Minimally Invasive LIVer And Simultaneous COlorectal Resection

Role: collaborator

NCT04366921Unknown

European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO

Role: collaborator

All 3 trials loaded